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In this interesting paper,1 the authors have successfully
quantiﬁed the predictive capabilities of the single-blind, Phase
IIa photosensitivity model. Most importantly, their conclusion
stresses that potential AEDs showing suppression of the patholog-
ical generalized epileptogenic reaction to Intermittent Photic
Stimulation (IPS) also show efﬁcacy in phase III double-blind
placebo-controlled AED trials of both partial and generalized
epilepsies. This is not surprising since photosensitivity (the photo-
paroxysmal EEG response, PPR) can occur in all different types of
epilepsies.
We would, however, like to put two main issues that are
addressed in the Discussion section into a broader perspective and
give advice for future proof of principle (PoP) intrapatient
photosensitivity studies based on what we have learned so far
from all trials, including those referred to by Yuen and Sims.1
1. Apparent discrepancy in results of CBZ in the
photosensitivity model—dose and formulation impact
the effect of CBZ
Binnie et al.2 found that CBZ produced a suppressive PPR
(positive effect) in the photosensitivity model; yet recently, French
et al.3 did not. The difference in conclusion reached likely can be
explained by:
(a) the formulation of CBZ used (CBZ liquid solution2 and tablets3)
and by
(b) the total time of IPS EEG recording post-dose.
CBZ tablets have a slow, variable absorption rate with peak
serum concentrations at hour 15 post-dose4; since CSF concentra-
tions are linearly correlated with serum, peak CSF/brain CBZ
concentrations would occur at 15 h post-single CBZ dose.5
Binnie’s2 use of a liquid CBZ formulation ensured an earlier rise
to, and greater peak CBZ concentration,6 and enhanced pharma-
codynamic effect,7 explaining its positive effect within a one-day
period.
The latest adaptive, double-blind CBZ trial3 was long, with four
distinct treatment days, comparing replicate placebo days with
days for single-dose CBZ 400 mg and with LEV 1000 mg. This trial
burden, with recurrent IPS sessions over weeks—due to wash-out
periods—was such that a choice was made to determine the effect
of drug or placebo for only 6 h post-dose, instead of the usual
testing over 32 h in Phase IIa AED development. Time is important
pharmacodynamically; while an AED PPR effect can coincide withhttp://dx.doi.org/10.1016/j.seizure.2014.08.002
1059-1311/ 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights reits’ peak plasma concentration, this is not always the case. While
valproate (VPA) is well-known to be clinically effective in patients
with photosensitive epilepsy, Rowan found a continued, delayed
effect of VPA in the model.8 Additionally, a muted effect of
intravenous VPA was seen in the model at 12 h post-continuous
infusion, postulating that VPA is an AED that may require both
appropriate concentration and time to exert its’ optimal effect.9
2. Publication bias as a possible ﬂaw to predict outcome of
future trials?
In general, many negative clinical trials do not get published, so
called ‘publication bias’.10 However, we do not believe that
publication bias exists for the IPS model. In fact, two studies with
negative results have been published—the above discussed retry of
CBZ,3 and a trial of ORG-637011 (increased photosensitivity and
spontaneous myoclonic jerks was observed). The authors’ state-
ment1 that ‘‘a positive photosensitivity PoP will not necessarily
guarantee future success in epilepsy efﬁcacy trials’’, based on
assumption of publication bias of positive trials only, is thus not
correct.
A caveat might be that investigators tend to use the
tremendously suppressive PPR effect of LEV and its’ analogues12
as a benchmark for any future potentially successful AED. VPA and
Lamotrigine have been much less effective in the model than
LEV.2,3
In summary, the three-day photosensitivity Phase IIa model in a
limited number of patient volunteers, with its adaptive dose-
ranging design, gives invaluable, fast and cost-effective informa-
tion on potency, dose/concentration–effect relationship and side-
effects of a potential AED. It can even be performed before
completion of long-term toxicity preclinical work. This PoP
knowledge allows us to better (and less expensively) construct
Phase IIb and III trials.
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